Drugs / Clifutinib
Clifutinib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07341672 | Dec 2026 → Apr 2027 expected | — | Sunshine Lake Pharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07211165 | Sep → Nov 2025 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05454098 | Nov → Dec 2022 | childhood acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04827069 | May 2018 → Aug 2023 | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05133882 | Oct 2022 → Dec 2027 expected | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05586074 | Mar 2023 → Nov 2027 expected | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clifutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05133882 ↗ |
| Known as | Clifutinib Besylate | “The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs” NCT05133882 ↗ |
| Known as | HEC73543 | “Clifutinib Besylate(HEC73543)” NCT04827069 ↗ |
| Route | Oral | “receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days” NCT04827069 ↗ |